Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

From the start of the pandemic, it was clear that some people who were infected with the coronavirus were experiencing more severe illness, which increased their chances of being hospitalised, admitted to an intensive care unit (ICU) or dying.

As we age, a weaker immune system and chronic health conditions could influence the way our body responds to the virus. Indeed, age is the biggest risk factor for developing severe COVID or dying from it. Over 70% of deaths attributed to COVID in the UK are in those aged 75 years and over.

Ethnicity, sex and obesity were also found to be risk factors for severe COVID outcomes. But, of course, we can’t do anything about our age, sex or ethnicity. We can do something about being overweight, though.

Body mass index (BMI) is a measure applying height and weight to calculate a weight score. A person with a BMI over 25 is considered to be overweight, and over 30 is considered to be obese.

Read the full article on The Conversation website, co-written by Nerys M AstburyCarmen Piernas and Min Gao (Nuffield Department of Primary Care Health Sciences).

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.